Heranba Industries Limited · NSE:HERANBA
Heranba Industries — Q2 FY2025 Earnings Presentation
30 slides from Heranba Industries's earnings presentation, Nov 13, 2024
Slide 1: Stock exchange filing cover letter
November 13, 2024 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor Dalal Street, Plot no. C/l, G Block, Mumbai- 400001, Bandra - Kurla Complex, Bandra (E), Mumbai - 400 051. Scrip Code: 543266 Symbol: HERANBA Dear Sir/Madam, Sub: Investor Pres
Slide 2: Investor Presentation Q2FY25
Investor Presentation Q2FY25 || November 2024 BSE: 543266 | NSE: HERANBA | ISIN: INE694N01015 www.heranba.co.in
Slide 3: Safe Harbor
Safe This presentation and the accompanying slides (the “Presentation”), which have been prepared by Heranba Industries Harbor Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any se
Slide 4: Contents
Contents Company Overview 01 SLIDE 04 Management Team 02 SLIDE 11 Quarterly Performance 03 SLIDE 13 Financial Performance 04 SLIDE 18 Strategy for Growth 05 SLIDE 25
Slide 5: Company Overview
Section: 01 Company Overview Heranba at glance Our journey Value chain SLIDE 05 SLIDE 06 SLIDE 07 Intermediaries Technicals Formulations SLIDE 08 SLIDE 09 SLIDE 10
Slide 6: Heranba at a Glance
Heranba at a Glance 60+ 4 65+ 1050+ Revenue from Institutional Manufacturing Countries Employees customers** Facilities Presence (as of FY24) (as of FY24) 8500+ 35% ~15% Dealers Revenue from Revenue from 7.8% Exports as % of sales Top 10 customers ROE# across India (as of FY24) (as of FY24) (as of F
Slide 7: Our Journey
Our Journey FORMULATIONS ISO CERTIFICATE EXPORTS Forward integrated into the Receipt of ISO 9001:2015 Exported Technicals and manufacturing of Formulations developed certification in respect of production Formulations to more ACQUISITION from Company’s synthetic pyrethroids & dispatch of agro Formul
Slide 8: Value Chain
Value Chain Manufacturing Process The process of manufacturing HIL manufactures a wide range of products, and each product has its can be classified broadly into own unique manufacturing process three stages Value Chain The Company specializes in the manufacturing processes that mainly include
Slide 9: Intermediaries
Intermediaries Cypermethric Acid Chloride (CMAC) End-use High CIS CMA High Trans CMA Intermediates manufactured are for Company’s own captive consumption for manufacturing various Technicals and Formulations Metaphenoxy High Trans CMAC Bromobenzenes Benzaldehyde (MPBD)
Slide 10: Technicals
Technicals Herbicides Glyphosate Metribuzin Insecticides Clodinofop Cypermethrin Deltamethrin Alpha Cypermethrin Acephate Lambda Cyhalothrin Permethrin Technicals Profenophos Temephos Theta Cypermethrin Thiamethoxam Imidacloprid Fungicides Tricyclazole Hexaconazole
Slide 11: Formulations
Formulations Revenue from Technical and Formulations Herbicides (₹ in Crore) Glory Glory 71 Chakde Shera Insecticides Heraquat Pendant Jayam Zinta Atria Progress Plus Param Cypraplus Dyken 967 Mantra Formulations 857 763 Astron 648 638 636 554 Signor 468 390 362 344
Slide 12: Management
An ISO 9001:2015 Company (@) HERANBA INDUSTRIES LIMITED Section: 02 Management
Slide 13: Experienced Promoters with Domain Knowledge
Experienced Promoters with Domain Knowledge Promoters having a cumulative experience of more than six decades Mr. Sadashiv K. Shetty Mr. Raghuram K. Shetty Chairman and Executive Director Managing Director Holds a bachelor’s (physics and chemistry) and master’s (chemistry) Holds a bachelor’s deg
Slide 14: Quarterly Performance
Section: 03 Quarterly Performance Management Quarterly P&L Summary Commentary Performance SLIDE 16 & 17 SLIDE 14 SLIDE 15
Slide 15: H1 FY25 Management Commentary
H1 FY25 Management Commentary Mr. Raghuram K. Shetty, Managing Director of Heranba Industries Limited, commented, “I am pleased to report that we have maintained our growth momentum in the first half of FY25 by reporting a strong set of numbers. We saw an increase of 5% in our revenues and 54 Crores
Slide 16: Quarterly Performance (Standalone)
Quarterly Performance (Standalone) Net Revenue from EBITDA(incl. Other Rev) PAT and PAT Margin Business Mix Operations and EBITDA Margin ( ₹ I N CR O R E & % ) (IN %) ( ₹ I N CR O R E ) ( I N ₹ CR O R E & % ) 500 20.00% 12.00% 10% 7% 12% 450 18.00% 10.00% 16.00% 11.30% 13.07% 400 7.60% 7.58% 14.00%
Slide 17: Profit & Loss Summary (Standalone)
Profit & Loss Summary (Standalone) (Quarterly) Figures in Crores, except EPS and Margins PARTICULARS Q2FY24 Q1FY25 Q2FY25 Revenue from Operations 429.51 304.35 457.64 Other Income 5.25 9.19 12.72 Total Revenue 434.76 313.54 470.36 Total Expenses 390.79 266.78 422.10 Profit Before Tax 43.98 46.76 48.
Slide 18: Profit & Loss Summary (Consolidated)
Profit & Loss Summary (Consolidated) (Quarterly) Figures in Crores, except EPS and Margins PARTICULARS Q2FY24 Q1FY25 Q2FY25 Revenue from Operations 424.29 296.25 437.42 Other Income 1.84 1.14 3.06 Total Revenue 426.13 297.39 440.48 Total Expenses 388.32 273.76 397.56 Profit Before Tax 37.81 23.63 42
Slide 19: Financial Performance
Section: 04 Financial Performance Key Ratios Financial Summary SLIDE 19 SLIDE 21
Slide 20: Key Financial Metrics (Standalone)
Key Financial Metrics (Standalone) Net Revenue EBITDA(incl. Other Rev) PAT and Net Debt/(Cash) from Operations and EBITDA Margin PAT Margin and Equity ( ₹ I N CR O R E ) ( I N ₹ CR O R E & % ) ( ₹ I N CR O R E & % ) ( ₹ I N CR O R E ) 189.31 13.04% 12.66% 18.63% 18.99% 117.07 9.11% 8.31% 15.4% 5.20%
Slide 21: Standalone Business Mix
Standalone Business Mix Diversified customers base across geographies helps to mitigate risks and benefit from expected growth in agrochemical market Revenue from Operations Revenue from Domestic / Exports (IN%) (% OF SALES) Export Revenue Split: Technical and Formulations Export 16% 23% 22% 32% 28%
Slide 22: Profit & Loss Summary (Standalone)
Profit & Loss Summary (Standalone) (₹ IN CRORE) PARTICULARS FY21 FY22 FY23 FY24 H1FY25 Revenue from Operations 1218.65 1450.37 1324.38 1274.75 761.99 Other Income 7.03 19.35 13.58 30.39 21.90 Total Revenue 1225.68 1469.72 1337.96 1305.14 783.90 Total Expenses 1017.39 1214.47 1193.82 1214.75 688.88 P
Slide 23: Standalone Balance Sheet (1/2)
Standalone Balance Sheet (1/2) (₹ IN CRORE) PARTICULARS FY21 FY22 FY23 FY24 H1FY25 Non-Current Assets Property, plant and equipment 133.44 193.42 185.99 239.66 229.71 Capital work-in-progress 9.70 14.23 42.04 11.32 13.81 Financial Assets: (i) Investments 10.10 2.13 0.92 1.83 2.55 (ii) Loans 53.19 29
Slide 24: Standalone Balance Sheet (2/2)
Standalone Balance Sheet (2/2) (₹ IN CRORE) PARTICULARS FY21 FY22 FY23 FY24 H1FY25 Equity and liabilities Equity Equity share capital 40.01 40.01 40.01 40.01 40.01 Other equity 488.12 674.44 776.10 837.45 901.67 Total Equity 528.13 714.45 816.11 877.46 941.69 Liabilities Non-Current Liabilities Fina
Slide 25: Standalone Cashflow Statement
Standalone Cashflow Statement (₹ IN CRORE) PARTICULARS FY21 FY22 FY23 FY24 H1FY25 Cash Flow from Operations 60.4 98.11 122.50 149.41 96.79 Cash Flow from Investing Activities (40.71) (81.72) (100.06) (266.71) (127.39) Cash Flow from financing Activities 61.9 (6.27) (18.08) 29.93 31.94 Net increase/
Slide 26: Consolidated Cashflow Statement
Consolidated Cashflow Statement (₹ IN CRORE) PARTICULARS FY24 H1FY25 Cash Flow from Operations 107.20 63.74 Cash Flow from Investing Activities (240.91) (128.62) Cash Flow from financing Activities 62.02 52.73 Net increase/ (decrease) in cash and cash equivalents (71.69) (12.15) Cash and cash equiva
Slide 27: Strategy for growth
Section: 05 Strategy for growth Competetive Strengths Business Strategy SLIDE 26 SLIDE 27
Slide 28: Competitive Strengths
Competitive Strengths Experienced Promoters and Management Team Wide Distribution Wide range of products Network across value chain Integrated Diversified Manufacturing Units Customer Base Exports to more Product Registration than 60 countries enabling global outreach
Slide 29: Business Strategy
Business Strategy Well positioned to exploit opportunities offered by growth in Agrochemicals Entering Highly Strengthening of Enhancing Enhancing Branded Regulated USA and R&D Facility Production Formulation Formulations and Europe markets Capabilities & Technicals in Public Health International Ma
Slide 30: Thank You
Corporate Office Heranba Industries Ltd. 2nd Floor, A Wing, Fortune Avirahi, Jain Derasar Lane, Near Moksh Plaza, Borivali (West), Mumbai – 400092 (India) Tel : 91-22-2898 7912/14, 91-22-2898 2133/44, 91-22-2898 4439, 91-22-5070 5050 Thank You Email : compliance@heranba.com